{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:03:00Z","timestamp":1788458580795,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Obsessive-compulsive disorder (OCD) is a neuropsychiatric condition characterized by the presence of intrusive thoughts, referred to as obsessions, and repetitive behaviors, known as compulsions. Globally, OCD affects approximately 2\u20133% of the population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Three databases (PubMed, Web of Science, and MEDLINE) were explored for the present study, from January 1, 2000 to December 31, 2024. The analysis was conducted using R version 4.3.2 to estimate the overall treatment effect of memantine and risperidone for OCD, relative to placebo, via meta-analysis. The Pooled Standardized Mean Differences (SMDs) were computed using both fixed-effect and random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Only 10 studies were included in current investigation, after identification of 2362 articles. Meta-analysis of memantine suggested statistically insignificant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.06) reduction in Y-BOCS score [SMD: \u20131.02 (\u20132.12, 0.08)], whereas meta-analysis of risperidone suggested statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.03) reduction in Y-BOCS score [SMD: \u20130.38 (\u20130.74, \u20130.02)].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Risperidone plays a significant role in reduction of Y-BOCS score in OCD patients, whereas memantine does not show a significant effect in reducing the Y-BOCS score in OCD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jfmpc.jfmpc_281_25","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:01:10Z","timestamp":1767013270000},"page":"4976-4983","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The effect of adjuvant treatment in obsessive compulsive disorder patients: A systematic review and meta-analysis"],"prefix":"10.4103","volume":"14","author":[{"given":"Ayush","family":"Pandey","sequence":"first","affiliation":[{"name":"MBBS, University College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, University College of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Dixit","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Medical Informatics, University College of Medical Sciences and GTB Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"(Suppl)","key":"R1-20251230","first-page":"5","article-title":"The cross national epidemiology of obsessive compulsive disorder. The cross national collaborative group","volume":"55","author":"Weissman","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"R3-20251230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11920-010-0127-5","article-title":"Scrupulosity:A unique subtype of obsessive-compulsive disorder","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Psychiatry Rep"},{"key":"R4-20251230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.janxdis.2014.06.003","article-title":"Musical obsessions:A comprehensive review of neglected clinical phenomena","volume":"28","author":"Taylor","year":"2014","journal-title":"J Anxiety Disord"},{"key":"R5-20251230","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/B978-0-444-64076-5.00049-1","article-title":"Genetic susceptibility in obsessive-compulsive disorder","volume":"148","author":"Fernandez","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"R6-20251230","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrn3962","article-title":"From the neuron doctrine to neural networks","volume":"16","author":"Yuste","year":"2015","journal-title":"Nat Rev Neurosci"},{"key":"R7-20251230","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5498\/wjp.v11.i9.568","article-title":"Antiglutamatergic agents for obsessive-compulsive disorder:Where are we now and what are possible future prospects?","volume":"11","author":"Maraone","year":"2021","journal-title":"World J Psychiatry"},{"key":"R8-20251230","doi-asserted-by":"crossref","first-page":"114606","DOI":"10.1016\/j.bbr.2023.114606","article-title":"Tourette syndrome and obsessive-compulsive disorder:A comprehensive review of structural alterations and neurological mechanisms","volume":"453","author":"Shitova","year":"2023","journal-title":"Behav Brain Res"},{"key":"R9-20251230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1176\/appi.ajp.2020.20111601","article-title":"Harmonizing the neurobiology and treatment of obsessive-compulsive disorder","volume":"178","author":"Goodman","year":"2021","journal-title":"Am J Psychiatry"},{"key":"R10-20251230","doi-asserted-by":"crossref","first-page":"e3000","DOI":"10.1002\/brb3.3000","article-title":"Obsessive-compulsive disorder:Etiology, neuropathology, and cognitive dysfunction","volume":"13","author":"Jalal","year":"2023","journal-title":"Brain Behav"},{"issue":"(7 Suppl)","key":"R11-20251230","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"(Suppl 1)","key":"R12-20251230","first-page":"S51","article-title":"Antipsychotic augmentation in the treatment of obsessive-compulsive disorder","volume":"61","author":"Thamby","year":"2019","journal-title":"Indian J Psychiatry"},{"key":"R13-20251230","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement:An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R14-20251230","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/emermed-2020-209567","article-title":"Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews","volume":"37","author":"Amir-Behghadami","year":"2020","journal-title":"Emerg Med J"},{"key":"R15-20251230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials:Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R16-20251230","doi-asserted-by":"crossref","first-page":"e70007","DOI":"10.1111\/jhn.70007","article-title":"Unlocking the vitamin puzzle:Investigating levels in people with Alzheimer's disease versus healthy controls through systematic review and network meta-analysis","volume":"38","author":"Marwaha","year":"2025","journal-title":"J Hum Nutr Diet"},{"key":"R17-20251230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12888-021-03642-z","article-title":"Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder:A double-blind placebo-controlled, randomized clinical trial","volume":"22","author":"Askari","year":"2022","journal-title":"BMC Psychiatry"},{"key":"R18-20251230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder:A double-blind, placebo-controlled study","volume":"15","author":"Erzegovesi","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"key":"R19-20251230","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpsychires.2018.07.008","article-title":"Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder:Double-blind, randomized, placebo-controlled trial","volume":"104","author":"Farnia","year":"2018","journal-title":"J Psychiatr Res"},{"key":"R20-20251230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder:Randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J Psychiatr Res"},{"key":"R21-20251230","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R22-20251230","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment-resistant obsessive-compulsive disorder:A double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"R23-20251230","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"R24-20251230","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0043-120268","article-title":"Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder:A Randomized controlled trial","volume":"51","author":"Modarresi","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R25-20251230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/JCP.0000000000000651","article-title":"Memantine as an adjuvant treatment for obsessive compulsive symptoms in manic phase of bipolar disorder:A randomized, double-blind, placebo-controlled clinical trial","volume":"37","author":"Sahraian","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"R26-20251230","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder:A randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"R27-20251230","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0193-953X(05)70181-7","article-title":"Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder","volume":"23","author":"Saxena","year":"2000","journal-title":"Psychiatr Clin North Am"},{"key":"R28-20251230","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00213-004-1847-1","article-title":"Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder:A preliminary study","volume":"174","author":"Arnold","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R29-20251230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00213-010-1808-9","article-title":"The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder","volume":"210","author":"Albelda","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R30-20251230","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder:Randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"R31-20251230","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"key":"R32-20251230","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.biopsych.2005.12.012","article-title":"Functional magnetic resonance imaging study of regional brain activation during implicit sequence learning in obsessive-compulsive disorder","volume":"61","author":"Rauch","year":"2007","journal-title":"Biol Psychiatry"},{"key":"R33-20251230","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archpsyc.61.7.720","article-title":"Mapping structural brain alterations in obsessive-compulsive disorder","volume":"61","author":"Pujol","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"R34-20251230","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-2000-8360","article-title":"Serotonin and dopamine antagonism in obsessive-compulsive disorder:Effect of atypical antipsychotic drugs","volume":"33","author":"Ramasubbu","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"R35-20251230","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","article-title":"5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia:A PET investigation","volume":"155","author":"Kapur","year":"1998","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_281_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:56:34Z","timestamp":1786647394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_281_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_281_25","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-02-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}